The previous-generation sensor originally launched in France last fall. At that time, it covered patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.
Now, the company can offer its continuous glucose monitor (CGM) technology to people in France aged over two years on on-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c ≥ 8%). France becomes the first country in Europe offering full national reimbursement for Dexcom CGM technology for those treating type 2 diabetes with basal injections. The country follows others around the world in that sense, including the U.S. and New Zealand.
Get the full story on our sister site, Drug Delivery Business News.
